STRO · Company research
Sutro Biopharma, Inc. (STRO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Liquidity Mapping Around (STRO) Price Events - Stock Traders Daily | Liquidity Mapping Around (STRO) Price Events Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 19, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma Stock Price Forecast. Should You Buy STRO? - StockInvest.us | Sutro Biopharma Stock Price Forecast. Should You Buy STRO? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma (STRO) Stock Forecast and Price Target 2026 $STRO - MarketBeat | Sutro Biopharma (STRO) Stock Forecast and Price Target 2026 $STRO MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma (STRO) Pulls Back 6.85% to $14.27 as Shares Test Key Support Zone - Volume Nodes - https://www.siam.in/ | Sutro Biopharma (STRO) Pulls Back 6.85% to $14.27 as Shares Test Key Support Zone - Volume Nodes https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 11, 2026 | neutral | 0 | 0.6 |
| An oncology dealmaker with partnerships worth over $2 billion joins Sutro - Stock Titan | An oncology dealmaker with partnerships worth over $2 billion joins Sutro Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| SaaS stocks, supposedly doomed by AI, are soaring! Will strong earnings from CRM, OKTA, and CRWD debunk the "end-of-SaaS" narrative? - Moomoo | SaaS stocks, supposedly doomed by AI, are soaring! Will strong earnings from CRM, OKTA, and CRWD debunk the "end-of-SaaS" narrative? Moomoo | View source ↗ | Moomoo | Aug 27, 2026 | neutral | 0 | 0.6 |
| Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher - Simply Wall Street | Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher Simply Wall Street | View source ↗ | Simply Wall Street | Aug 17, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma (NasdaqGM:STRO) Stock Forecast & Analyst Predictions - Simply Wall Street | Sutro Biopharma (NasdaqGM:STRO) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Aug 16, 2026 | neutral | 0 | 0.6 |
| STRO Stock Plummets 15% — What Drove The Selloff? - Yahoo Finance | STRO Stock Plummets 15% — What Drove The Selloff? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study - Yahoo Finance | Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| STRO Stock Plummets 15% — What Drove The Selloff? - Stocktwits | STRO Stock Plummets 15% — What Drove The Selloff? Stocktwits | View source ↗ | Stocktwits | Aug 12, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma Reports $9.8 Million Revenue in Q2 2026 | STRO Stock News - Quiver Quantitative | Sutro Biopharma Reports $9.8 Million Revenue in Q2 2026 | STRO Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 12, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma, Inc. Common Stock (STRO) Stock Price: Oct 16 Close $10.94 - Gotrade | Sutro Biopharma, Inc. Common Stock (STRO) Stock Price: Oct 16 Close $10.94 Gotrade | View source ↗ | Gotrade | Jul 15, 2026 | neutral | 0 | 0.6 |
| STRO Forecast — Price Target — Prediction for 2027 - TradingView | STRO Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results - Yahoo Finance | US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results Yahoo Finance | View source ↗ | Yahoo Finance | May 17, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell - Seeking Alpha | Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell Seeking Alpha | View source ↗ | Seeking Alpha | Apr 30, 2026 | neutral | 0 | 0.6 |
| Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why - Stocktwits | Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why Stocktwits | View source ↗ | Stocktwits | Apr 7, 2026 | neutral | 0 | 0.6 |
| Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 (NASDAQ:STRO) - Seeking Alpha | Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 (NASDAQ:STRO) Seeking Alpha | View source ↗ | Seeking Alpha | Mar 13, 2026 | neutral | 0 | 0.6 |
| $STRO stock is down 9% today. Here's what we see in our data. - Quiver Quantitative | $STRO stock is down 9% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Mar 9, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.